Radiopharm Theranostics (NASDAQ:RADX) Trading 4.6% Higher – Time to Buy?

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) shares shot up 4.6% during trading on Thursday . The company traded as high as $4.47 and last traded at $4.33. 24,689 shares changed hands during mid-day trading, an increase of 18% from the average daily volume of 20,944 shares. The stock had previously closed at $4.14.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. HC Wainwright started coverage on Radiopharm Theranostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $11.00.

Radiopharm Theranostics Price Performance

The business’s 50-day moving average is $4.47 and its 200 day moving average is $4.78.

Institutional Investors Weigh In On Radiopharm Theranostics

A number of hedge funds and other institutional investors have recently modified their holdings of RADX. PNC Financial Services Group Inc. boosted its holdings in Radiopharm Theranostics by 100.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock valued at $88,000 after acquiring an additional 8,000 shares during the period. Marex Group plc bought a new position in Radiopharm Theranostics during the 4th quarter worth approximately $54,000. Jane Street Group LLC purchased a new position in Radiopharm Theranostics in the 4th quarter worth approximately $76,000. Virtu Financial LLC purchased a new position in Radiopharm Theranostics in the 4th quarter worth approximately $76,000. Finally, Hsbc Holdings PLC purchased a new position in Radiopharm Theranostics in the 4th quarter worth approximately $1,007,000.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.